Peptide dosing protocols

Typical dose

0.25 mg → 2.4 mg weekly

Frequency

Once weekly, subcutaneous

Cycle

Titrate every 4 weeks; ongoing maintenance

Reconstitution

5 mg vial + 2 mL bacteriostatic water = 2.5 mg/mL

Most protocols hold each step 4 weeks before escalating. Many people stay at a lower step when appetite control is already effective.

Typical dose

2.5 mg → 15 mg weekly

Frequency

Once weekly, subcutaneous

Cycle

Titrate every 4 weeks; ongoing maintenance

Reconstitution

30 mg vial + 3 mL bacteriostatic water = 10 mg/mL

Dual GIP/GLP-1 agonist. Nausea is most common in the first week after each step up.

Typical dose

1 mg → 12 mg weekly

Frequency

Once weekly, subcutaneous

Cycle

Titrate every 4 weeks

Reconstitution

20 mg vial + 2 mL bacteriostatic water = 10 mg/mL

Triple agonist (GIP/GLP-1/glucagon). Investigational — literature is still early.

Typical dose

250–500 mcg daily

Frequency

Once daily, morning, fasted

Cycle

8–12 weeks

Reconstitution

5 mg vial + 2 mL water = 2.5 mg/mL (100 units = 250 mcg)

Fragment of hGH studied for fat metabolism without effects on blood sugar.

Typical dose

250–500 mcg daily

Frequency

Once or twice daily, subcutaneous near the target area

Cycle

4–8 weeks, then a break of equal length

Reconstitution

5 mg vial + 2 mL water = 2.5 mg/mL

Commonly paired with TB-500 in recovery protocols.

Typical dose

2–2.5 mg twice weekly (loading), then 2 mg weekly

Frequency

2× weekly loading for 4–6 weeks, then weekly maintenance

Cycle

6–8 week loading, 4+ week maintenance

Reconstitution

10 mg vial + 5 mL water = 2 mg/mL

Often paired with BPC-157 in soft-tissue recovery protocols.

Typical dose

1–2 mg daily (injectable) or topical serum

Frequency

Daily

Cycle

4–8 weeks

Reconstitution

50 mg vial + 5 mL water = 10 mg/mL

Copper peptide studied for skin, collagen, and wound-healing endpoints.

Typical dose

200–300 mcg per dose

Frequency

1–3× daily, before bed and/or post-workout, fasted

Cycle

8–12 weeks, then 4 weeks off

Reconstitution

5 mg vial + 2 mL water = 2.5 mg/mL

Selective GH secretagogue; frequently stacked with CJC-1295.

Typical dose

100–200 mcg per dose

Frequency

1–3× daily, fasted

Cycle

8–12 weeks, then 4 weeks off

Reconstitution

5 mg vial + 2 mL water = 2.5 mg/mL

Short half-life version dosed with Ipamorelin to mimic natural GH pulses.

Typical dose

1–2 mg daily

Frequency

Once daily at bedtime

Cycle

12–26 weeks

Reconstitution

10 mg vial + 2 mL water = 5 mg/mL

Most studied for visceral fat endpoints.

Typical dose

200–500 mcg daily

Frequency

Once daily at bedtime, fasted

Cycle

12 weeks, then reassess

Reconstitution

5 mg vial + 2 mL water = 2.5 mg/mL

GHRH analog with a very short half-life; nightly dosing is typical.

Typical dose

50–100 mg daily (subcutaneous)

Frequency

Daily or every other day

Cycle

4 weeks on, 2 weeks off

Reconstitution

Supplied in solution or 500 mg vial + 5 mL water = 100 mg/mL

Injecting quickly can cause flushing or chest pressure; slow administration is standard.

Typical dose

200–600 mg

Frequency

2–3× weekly

Cycle

8–12 weeks

Reconstitution

Supplied in solution or per vial label

Antioxidant support; often paired with NAD+ or B12 in wellness protocols.

Typical dose

5–10 mg

Frequency

2–3× weekly

Cycle

4–8 weeks

Reconstitution

10 mg vial + 2 mL water = 5 mg/mL

Mitochondrial-derived peptide studied for metabolic and exercise endpoints.

Typical dose

5–10 mg daily

Frequency

Once daily

Cycle

10–20 days, 2–3 times per year

Reconstitution

50 mg vial + 5 mL water = 10 mg/mL

Short pulsed courses rather than continuous dosing.

Typical dose

0.5–1.75 mg

Frequency

As needed, 45 minutes to 2 hours before activity; max once per 24 h

Cycle

No more than 8 doses per month

Reconstitution

10 mg vial + 5 mL water = 2 mg/mL

Flushing and nausea are the most reported effects; start at the low end.

Typical dose

1.5–3 mg

Frequency

2× weekly

Cycle

4–8 weeks

Reconstitution

5 mg vial + 2 mL water = 2.5 mg/mL

Studied for immune modulation endpoints.

Typical dose

250–500 mcg daily

Frequency

Daily, intranasal or subcutaneous

Cycle

2–4 weeks

Reconstitution

5 mg vial + 2 mL water = 2.5 mg/mL

Peptide analog of tuftsin studied for anxiolytic endpoints.